Skip to content

US · NAUT · BIOTECHNOLOGY

Nautilus Biotechnolgy, Inc. (NAUT) intrinsic value and stock valuation

$2.12as of 2026-11-21 · Mkt cap 118.35M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nautilus Biotechnolgy, Inc. DCF and intrinsic value

InvestorsCraft values NAUT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NAUT’s statements →

Nautilus Biotechnolgy, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Seattle, WA 98102 nautilus.bio

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-59M
20182025
Free cash flow
-$-51.97M
20182025
Total equity
$157M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-66.84M-$-81.48M-$-76.15M-$-63.62M-$-50.5M
Net income-$-59M-$-70.78M-$-63.67M-$-57.92M-$-50.31M
EPSd-$-467.29K-$-564.3K-$-509.69K-$-464.88K-$-595.67K
Operating cash flow-$-50.7M-$-59.15M-$-51.71M-$-45.81M-$-39.24M
Capital expenditure-$-1.28M-$-2.12M-$-2.44M-$-2.32M-$-2.27M
Free cash flow-$-51.97M-$-61.27M-$-54.15M-$-48.13M-$-41.51M
Total assets$191.1M$242.7M$305.6M$350.1M$398.5M
Total debt$30M$30.5M$34.6M$30.3M$30M
Net debt$17.6M$2.83M$15.2M-$-84.19M-$-155.59M
Total equity$157M$208.7M$265.4M$314.9M$363.6M
Cash and short-term investments$103.4M$129.9M$173.4M$184.5M$345.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$6.46M$6.35M$5.71M$0.00$2.84M
Gross profit-$-6.46M-$-6.35M-$-5.71M$0.00-$-2.84M
Research and development expenses$41.1M$50.5M$47.3M$37.7M$26.5M
Selling, general and administrative expenses$25.7M$31M$28.9M$26M$21.2M
Other expenses-$-6.46M-$-6.35M-$-5.71M$0.00$0.00
Operating expenses$60.4M$75.1M$70.5M$63.6M$47.7M
Cost and expenses$66.8M$81.5M$76.2M$63.6M$50.5M
Interest income$7.87M$10.8M$12.6M$5.82M$330K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$6.46M$6.35M$1.85M$3.42M$2.84M
Ebitda-$-52.54M-$-64.43M-$-61.83M-$-60.08M-$-47.47M
Operating income-$-66.84M-$-81.48M-$-76.15M-$-63.62M-$-50.5M
Total other income/expenses, net$7.84M$10.7M$12.5M$5.69M$180K
Income before tax-$-59M-$-70.78M-$-63.67M-$-57.92M-$-50.31M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-59M-$-70.78M-$-63.67M-$-57.92M-$-50.31M
Weighted average shares outstanding$126.3M$125.4M$124.9M$124.6M$84.5M
Weighted average diluted shares outstanding$126.3M$125.4M$124.9M$124.6M$84.5M
Balance sheet
20252024202320222021
Cash and short-term investments$103.4M$129.9M$173.4M$184.5M$345.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$106M$132.8M$176.8M$187.2M$349.2M
Property, plant and equipment, net$31.2M$32.3M$36.9M$32.6M$31.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$52.7M$76.4M$90.7M$129.2M$16.4M
Total non-current assets$85.2M$109.9M$128.7M$162.8M$49.2M
Total assets$191.1M$242.7M$305.6M$350.1M$398.5M
Accounts payable$940K$990K$1.64M$1.27M$1.72M
Short-term debt$3.83M$4.1M$3.54M$1.99M$970K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.95M$7.63M$9.12M$6.79M$5.81M
Long-term debt$26.2M$26.4M$31.1M$28.3M$29.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$26.2M$26.4M$31.1M$28.3M$29.1M
Capital lease obligations$30M$30.5M$34.6M$30.3M$30M
Total liabilities$34.1M$34M$40.2M$35.1M$34.9M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-332.02M-$-273.02M-$-202.24M-$-138.56M-$-80.64M
Accumulated other comprehensive income (loss)$240K$60K-$-260K-$-1.85M-$-180K
Total equity$157M$208.7M$265.4M$314.9M$363.6M
Total investments$143.8M$178.7M$244.7M$199.1M$176.5M
Total debt$30M$30.5M$34.6M$30.3M$30M
Net debt$17.6M$2.83M$15.2M-$-84.19M-$-155.59M
Cash flow statement
20252024202320222021
Net income-$-59M-$-70.78M-$-63.67M-$-57.92M-$-50.31M
Depreciation and amortization$6.46M$6.35M$5.71M$3.42M$2.84M
Stock-based compensation$6.84M$12.7M$12.1M$10.4M$7.93M
Change in working capital-$-3.58M-$-5.46M-$-3.22M-$-790K-$-20K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-70K-$-580K$390K-$-560K$1.26M
Net cash provided by operating activities-$-50.7M-$-59.15M-$-51.71M-$-45.81M-$-39.24M
Investments in property, plant and equipment-$-1.28M-$-2.12M-$-2.44M-$-2.32M-$-2.27M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$35.2M$66.3M-$-43.73M-$-25.74M-$-138.96M
Common stock issued$210K$1.14M$370K$560K-$-7.96M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$210K$1.14M$370K$560K$327.5M
Net change in cash-$-15.26M$8.25M-$-95.08M-$-70.98M$149.2M
Cash at end of period$13.4M$28.7M$20.4M$115.5M$186.5M
Operating cash flow-$-50.7M-$-59.15M-$-51.71M-$-45.81M-$-39.24M
Capital expenditure-$-1.28M-$-2.12M-$-2.44M-$-2.32M-$-2.27M
Free cash flow-$-51.97M-$-61.27M-$-54.15M-$-48.13M-$-41.51M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nautilus Biotechnolgy, Inc.

        Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

        CEO
        Sujal Patel
        Employees
        130
        Beta
        0.81

        Explore

        Frequently asked questions

        What is the intrinsic value of Nautilus Biotechnolgy, Inc. (NAUT)?

        InvestorsCraft does not currently publish an intrinsic value for NAUT. How the IC value is calculated.

        Is NAUT undervalued?

        InvestorsCraft does not publish an undervaluation signal for NAUT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.